Advances in hematopoietic stem cell transplantation for primary immunodeficiency

Expert Review of Clinical Immunology

Volumn 9, Issue 10, 2013, Pages 991-999

  Slatter, Mary A ^a,b   Gennery, Andrew R ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b Newcastle Upon Tyne Hospitals NHS Foundation Trust   (United Kingdom)

Author keywords

extracorporeal photopheresis; graft versus host disease; mesenchymal stromal cells; newborn screening for severe combined immunodeficiency; primary immunodeficiency; reduced intensity conditioning; severe combined immunodeficiency; targeted busulfan; treosulfan

Indexed keywords

BUSULFAN; TREOSULFAN;

GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; IMMUNE DEFICIENCY; INFECTION; REDUCED INTENSITY CONDITIONING; REVIEW;

ANIMALS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; STEM CELL NICHE; TRANSPLANTATION CONDITIONING;

EID: 84886904259     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2013.836061     Document Type: Review

References (59)

1. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2(7583), 1366-1369 (1968).
2. Bach FH, Albertini RJ, Joo P, Anderson JL, Bortin MM. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 2(7583), 1364-1366 (1968).
3. Gennery AR, Slatter MA, Grandin L et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J. Allergy Clin. Immunol. 126, 602-610.e1-e11 (2010).
4. Rao K, Amrolia PJ, Jones A et al. Improved survival after unrelated bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 105, 979-985 (2005).
5. Ritchie DS, Seymour JF, Roberts AW, Szer J, Grigg AP. Acute left ventricular failure following melphalan and fludarabine conditioning. Bone Marrow Transplant. 28, 101-103 (2001).
6. Burroughs LM, Storb R, Leisenring WM et al. Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders. Bone Marrow Transplant. 40, 633-642 (2007).
7. Straathof KC, Rao K, Eyrich M et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 374, 912-920 (2009).
8. Slatter MA, Gennery AR, Cheetham TD et al. Thyroid dysfunction after bone marrow transplantation for primary immunodeficiency without the use of total body irradiation in conditioning. Bone Marrow Transplant. 33, 949-953 (2004).
9. Malar R, Sjoö F, Rentsch K, Hassan M, Güngor T. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr. Transplant. 15, 580-588 (2011).
10. Güngor T, Albert MH, Teira P et al. Excellent outcome after submyeloablative reduced-toxicity conditioning and hematopoietic stem cell transplantation in high-risk chronic granulomatous disease patients. Lancet (2013) (In Press).
11. Seger RA, Gungor T, Belohradsky BH et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood 100, 4344-4350 (2002).
12. Beelen DW, Trenschel R, Casper J et al. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. Bone Marrow Transplant. 35, 233-2341 (2005).
13. Casper J, Holowiecki J, Trenschel R et al. Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning. Bone Marrow Transplant. 47, 1171-1177 (2012).
14. Greystoke B, Bonanomi S, Carr TF et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br. J. Haematol. 142, 257-262 (2008).
15. Cutting R, Mirelman A, Vora A. Treosulphan as an alternative to busulphan for myeloablative conditioning in paediatric allogeneic transplantation. Br. J. Haematol. 143, 748-745 (2008).
16. Slatter M, Rao K, Amrolia P et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 117, 4367-4375 (2011).
17. Wachowiak J, Sykora KW, Cornish J et al Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party. Bone Marrow Transplant. 46, 1510-1518 (2011).
18. Beier R, Schulz A, Honig M et al Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience. Bone Marrow Transplant. 48, 491-501 (2013).
19. Bernardo ME, Piras E, Vacca A et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 120, 473-476 (2012).
20. Corbacioglu S, Greil J, Peters C et al Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 33, 189-195 (2004).
21. Corbacioglu S, Cesaro S, Faraci M et al Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet 379, 1301-1309 (2012).
22. Dvorak CC, Gilman AL, Horn B et al Haploidentical related-donor hematopoietic cell transplantation in children using megadoses of CliniMACs-selected CD34(+) cells and a fixed CD3(+) dose. Bone Marrow Transplant. 48, 508-513 (2013).
23. Slatter MA, Brigham K, Dickinson AM et al. Long-term immune reconstitution after anti-CD52-treated or anti-CD34-treated hematopoietic stem cell transplantation for severe T-lymphocyte immunodeficiency. J. Allergy Clin. Immunol. 121, 361-367 (2008).
24. Devine SM, Bartholomew AM, Mahmud N et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp. Hematol. 29, 244-55 (2001).
25. Slatter M, Nademi Z, Patel S et al. Haploidentical hematopoietic stem cell transplantation can lead to viral clearance in severe combined immunodeficiency. J. Allergy Clin. Immunol. 131, 1705-1708.e1 (2013).
26. Oevermann L, Lang P, Feuchtinger T et al. Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation. Ann. NY Acad. Sci. 1266, 161-170 (2012).
27. Jol-van der Zijde CM, Bredius RG, Jansen-Hoogendijk AM et al. IgG antibodies to ATG early after pediatric hematopoietic SCT increase the risk of acute GVHD. Bone Marrow Transplant. 47, 360-368 (2012).
28. Chiesa R, Gilmour K, Qasim W et al. Omission of in vivo T-cell depletion promotes rapid expansion of naive CD4+ cord blood lymphocytes and restores adaptive immunity within 2 months after unrelated cord blood transplant. Br. J. Haematol. 156, 656-666 (2012).
29. Shaiegan M, Iravani M, Babaee G, Ghavamzadeh A. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients. Transpl. Immunol. 15, 223-227 (2006).
30. Choi SW, Kitko CL, Braun T et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 112, 1539-1542 (2008).
31. August KJ, Chiang KY, Bostick RM et al Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transplant. 46, 601-604 (2011).
32. Schots R, Kaufman L, Van Riet I et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 17, 1150-1156 (2003).
33. Paczesny S, Braun TM, Levine JE et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci. Transl. Med. 2, 13ra2 (2010).
34. Ferrara JL, Harris AC, Greenson JK et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 118, 6702-6708 (2011).
35. Harris AC, Ferrara JL, Braun TM et al. Plasma biomarkers of lower gastrointestinal and liver acute GVHD. Blood 119, 2960-2963 (2012).
36. Levine JE, Huber E, Hammer ST et al. Low Paneth cell numbers at onset of gastrointestinal GVHD identify patients at high risk for non-relapse mortality. Blood (2013) (Epub ahead of print).
37. Levine JE, Logan BR, Wu J et al. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 119, 3854-3860 (2012).
38. Le Blanc K, Rasmusson I, Sundberg B et al Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439-1441 (2004).
39. Ringden O, Uzunel M, Rasmusson I et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81, 1390-1397 (2006).
40. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a Phase II study. Lancet 371, 1579-1586 (2008).
41. Weng JY, Du X, Geng SX et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 45, 1732-1740 (2010).
42. Lucchini G, Introna M, Dander E et al. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population. Biol. Blood Marrow Transplant. 16, 1293-1301 (2010).
43. Baron F, Lechanteur C, Willems E et al. Co transplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) with-out abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol. Blood Marrow Transplant. 16, 838-847 (2010).
44. Prasad VK, Lucas KG, Kleiner GI et al. (2011) Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (prochymal) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. Biol Blood Marrow Transplant. 17, 534-541 (2011).
45. Dall'Amico R, Rossetti F, Zulian F et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br. J. Haematol. 97, 848-854 (1997).
46. Greinix HT, Volc-Platzer B, Rabitsch W et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 92, 3098-3104 (1998).
47. Rubegni P, Feci L, Poggiali S et al. Extracorporeal photopheresis: a useful therapy for patients with steroids refractory acute graft versus host disease but not for the prevention of the chronic form. Br. J. Dermatol. doi: 10.1111/bjd.12332 (2013) (Epub ahead of print).
48. Cole TS, Johnstone IC, Pearce MS et al. Outcome of children requiring intensive care following haematopoietic SCT for primary immunodeficiency and other non-malignant disorders. Bone Marrow Transplant. 47, 40-45 (2012).
49. Brown L, Xu-Bayford J, Allwood Z et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival outcome: the case for newborn screening. Blood 117, 3243-3246 (2011).
50. Buckley RH. The long quest for neonatal screening for severe combined immunodeficiency. J. Allergy Clin. Immunol. 129, 597-604 (2012).
51. Kwan A, Church JA, Cowan MJ et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: Results of the first 2 years. J. Allergy Clin. Immunol. 132, 140-150.e7 (2013).
52. la Marca G, Canessa C, Giocaliere E et al. Tandem mass spectrometry, but not T-cell receptor excision circle analysis, identifies newborns with late-onset adenosine deaminase deficiency. J. Allergy Clin. Immunol. 131, 1604-1610 (2013).
53. Gennery AR, Cant AJ. Diagnosis of severe combined immunodeficiency. J. Clin. Pathol. 54, 191-195 (2001).
54. Horn B, Cowan MJ. Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: need for safer conditioning and reduced late effects. J. Allergy Clin. Immunol. 131, 1306-1311 (2013).
55. Czechowicz A, Kraft D, Weissman IL, Bhattacharya D. Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 318, 1296-1299 (2007).
56. Haddad E, Leroy S, Buckley RH. B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? J. Allergy Clin. Immunol. 131, 994-1000 (2013).
57. Gerdemann U, Katari UL, Papadopoulou A et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for Adenovirus, EBV and CMV infections after allogeneic hematopoietic stem cell transplant. Mol. Ther. (2013) (Epub ahead of print).
58. Feuchtinger T, Opherk K, Bethge WA et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 116, 4360-4367 (2010).
59. Cole T, McKendrick F, Titman P et al. Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone haematopoietic stem cell transplant. J. Clin. Immunol. 33, 8-13 (2013).